Vanguard reports 93.3M-share, 7.51% stake in Gilead Sciences (NASDAQ: GILD)

Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock

Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade

Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Inc. stock outperforms competitors on strong trading day

Gilead Sciences Inc. stock outperforms competitors on strong trading day

Daniel O'Day (GILD) files Form 144 to sell 10,000 performance shares

Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know

Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. -- Barrons.com

Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc.

Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel

Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc.

Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel

Gilead Sciences Completes Acquisition of Arcellx and Anito-cel

Gilead fully acquires Arcellx (NASDAQ: ACLX) as tender offer and merger close

Gilead Sciences reports new GTPase KRAS G12D inhibitors and degraders

Gilead (NASDAQ: GILD) closes Arcellx deal, gains full control of anito-cel

Mitsubishi UFJ Trust & Banking Corp Decreases Stake in Gilead Sciences, Inc. $GILD